NCT06778447View on ClinicalTrials.gov

Clinical Trial Evaluating the Safety and Efficacy of Nucleus Pulposus Allograft in Participants With Degenerative Disc Disease

NARecruitingINTERVENTIONAL
Enrollment

496

Participants

Timeline

Start Date

February 17, 2025

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2028

Conditions
Degenerative Disc DiseaseDisc DegenerationLumbar Discogenic Pain
Interventions
OTHER

VIA Disc NP

VIA Disc NP is processed from donated cadaveric disc tissue, lyophilized, and micronized to particles.

OTHER

Sham

A 20G spinal needle will be carefully inserted through the skin and muscle of the back but WILL NOT penetrate the annulus fibrosus of the intervertebral disc. No saline or VIA Disc NP will be injected.

Trial Locations (2)

71101

RECRUITING

Spine Institute of Louisiana, Shreveport

80229

RECRUITING

Premier Spine and Pain Institute, Thornton

All Listed Sponsors
lead

VIVEX Biologics, Inc.

INDUSTRY